InvestorsHub Logo
Followers 45
Posts 4605
Boards Moderated 0
Alias Born 07/19/2006

Re: DewDiligence post# 2992

Friday, 05/31/2024 3:03:42 PM

Friday, May 31, 2024 3:03:42 PM

Post# of 3019
I think the odds of summary judgment in favor of PFE is higher than that for ENTA, but that the odds of no summary judgement for either is still the most likely outcome. The foundation for the active moiety does predate the pandemic after all bc the molecule is based on a structure designed for the virus that caused the earlier SARS outbreak in the early aughts. That said it does seem like the patent itself, if it stands, does cover paxlovid bc one of PFE's arguments that is public is that the patent was altered after the chemical structure of nirmatrelvir was revealed in 2021 so this could actually go in ENTA's favor as well if the judge really feel the patent shouldn't be invalidated

On April 6, 2021, at a virtual meeting of the American Chemical Society (“ACS”), Pfizer's scientists publicly revealed the chemical structure of nirmatrelvir.... It is Pfizer's position that significant revisions of the patent are based on Pfizer's work in developing nirmatrelvir, disclosed in the April 2021 presentation



https://casetext.com/case/enanta-pharm-v-pfizer-inc-2
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News